{
  "trial_id": "NCT03371355",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, body mass index (BMI), baseline fasting triglycerides level, baseline hemoglobin A1c (HbA1c), baseline hepatic fat fraction (HFF), duration of Type 2 diabetes mellitus, use of oral antidiabetic therapy, history of hepatic steatosis.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Body Mass Index (BMI)",
          "body mass index (BMI)"
        ],
        [
          "Fasting Triglycerides (TG)",
          "baseline fasting triglycerides level"
        ],
        [
          "Hemoglobin A1C (HbA1C)",
          "baseline hemoglobin A1c (HbA1c)"
        ],
        [
          "Hepatic Fat Fraction (HFF)",
          "baseline hepatic fat fraction (HFF)"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Angiopoietin Like 3 (ANGPTL3)",
        "Total Cholesterol (TC)",
        "Non- High density lipoprotein cholesterol (Non-HDL-C)",
        "High density lipoprotein cholesterol (HDL-C)",
        "Low Density Lipoprotein Cholesterol (LDL-C)",
        "Very Low Density Lipoprotein Cholesterol (VLDL-C)",
        "Apolipoprotein CIII (ApoCIII)",
        "Apolipoprotein A1 (ApoA1)",
        "Apolipoprotein B (ApoB)",
        "Apolipoprotein B48 (ApoB-48)",
        "Apolipoprotein B100 (ApoB-100)",
        "Lipoprotein-a (Lp[a])",
        "Free Fatty Acid (FFA)",
        "Insulin",
        "Plasma Glucose",
        "Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)",
        "Fructosamine",
        "Glycated Albumin",
        "Subcutaneous Adipose Tissue (SAT)",
        "Visceral Adipose Tissue (VAT)",
        "Fatty Liver Index (FLI)",
        "Body Weight",
        "Waist to Hip Ratio"
      ],
      "remaining_candidate_features": [
        "duration of Type 2 diabetes mellitus",
        "use of oral antidiabetic therapy",
        "history of hepatic steatosis."
      ]
    },
    "processed-gen-response": "Age, sex, race, body mass index (BMI), baseline fasting triglycerides level, baseline hemoglobin A1c (HbA1c), baseline hepatic fat fraction (HFF), duration of Type 2 diabetes mellitus, use of oral antidiabetic therapy, history of hepatic steatosis."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Plasma Triglycerides, Hepatic Fat Fraction, Hemoglobin A1c, Duration of Type 2 Diabetes, Use of Oral Antidiabetic Therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Body Mass Index (BMI)",
          "Body Mass Index"
        ],
        [
          "Fasting Triglycerides (TG)",
          "Plasma Triglycerides"
        ],
        [
          "Hemoglobin A1C (HbA1C)",
          "Hemoglobin A1c"
        ],
        [
          "Hepatic Fat Fraction (HFF)",
          "Hepatic Fat Fraction"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Angiopoietin Like 3 (ANGPTL3)",
        "Total Cholesterol (TC)",
        "Non- High density lipoprotein cholesterol (Non-HDL-C)",
        "High density lipoprotein cholesterol (HDL-C)",
        "Low Density Lipoprotein Cholesterol (LDL-C)",
        "Very Low Density Lipoprotein Cholesterol (VLDL-C)",
        "Apolipoprotein CIII (ApoCIII)",
        "Apolipoprotein A1 (ApoA1)",
        "Apolipoprotein B (ApoB)",
        "Apolipoprotein B48 (ApoB-48)",
        "Apolipoprotein B100 (ApoB-100)",
        "Lipoprotein-a (Lp[a])",
        "Free Fatty Acid (FFA)",
        "Insulin",
        "Plasma Glucose",
        "Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)",
        "Fructosamine",
        "Glycated Albumin",
        "Subcutaneous Adipose Tissue (SAT)",
        "Visceral Adipose Tissue (VAT)",
        "Fatty Liver Index (FLI)",
        "Body Weight",
        "Waist to Hip Ratio"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Duration of Type 2 Diabetes",
        "Use of Oral Antidiabetic Therapy"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Plasma Triglycerides, Hepatic Fat Fraction, Hemoglobin A1c, Duration of Type 2 Diabetes, Use of Oral Antidiabetic Therapy"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, HbA1c, Fasting Triglycerides, Liver Fat Fraction, Diabetes Duration, History of Cardiovascular Disease.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Body Mass Index (BMI)",
          "Body Mass Index"
        ],
        [
          "Hemoglobin A1C (HbA1C)",
          "HbA1c"
        ],
        [
          "Fasting Triglycerides (TG)",
          "Fasting Triglycerides"
        ],
        [
          "Hepatic Fat Fraction (HFF)",
          "Liver Fat Fraction"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Angiopoietin Like 3 (ANGPTL3)",
        "Total Cholesterol (TC)",
        "Non- High density lipoprotein cholesterol (Non-HDL-C)",
        "High density lipoprotein cholesterol (HDL-C)",
        "Low Density Lipoprotein Cholesterol (LDL-C)",
        "Very Low Density Lipoprotein Cholesterol (VLDL-C)",
        "Apolipoprotein CIII (ApoCIII)",
        "Apolipoprotein A1 (ApoA1)",
        "Apolipoprotein B (ApoB)",
        "Apolipoprotein B48 (ApoB-48)",
        "Apolipoprotein B100 (ApoB-100)",
        "Lipoprotein-a (Lp[a])",
        "Free Fatty Acid (FFA)",
        "Insulin",
        "Plasma Glucose",
        "Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)",
        "Fructosamine",
        "Glycated Albumin",
        "Subcutaneous Adipose Tissue (SAT)",
        "Visceral Adipose Tissue (VAT)",
        "Fatty Liver Index (FLI)",
        "Body Weight",
        "Waist to Hip Ratio"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Diabetes Duration",
        "History of Cardiovascular Disease."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, HbA1c, Fasting Triglycerides, Liver Fat Fraction, Diabetes Duration, History of Cardiovascular Disease."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), weight, height, plasma triglycerides (TG) level, hemoglobin A1c (HbA1c) level, hepatic fat fraction (HFF), history of oral antidiabetic therapy, duration of Type 2 diabetes mellitus, history of hypertriglyceridemia, history of nonalcoholic fatty liver disease (NAFLD).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Body Mass Index (BMI)",
          "body mass index (BMI)"
        ],
        [
          "Fasting Triglycerides (TG)",
          "plasma triglycerides (TG) level"
        ],
        [
          "Hemoglobin A1C (HbA1C)",
          "hemoglobin A1c (HbA1c) level"
        ],
        [
          "Hepatic Fat Fraction (HFF)",
          "hepatic fat fraction (HFF)"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Angiopoietin Like 3 (ANGPTL3)",
        "Total Cholesterol (TC)",
        "Non- High density lipoprotein cholesterol (Non-HDL-C)",
        "High density lipoprotein cholesterol (HDL-C)",
        "Low Density Lipoprotein Cholesterol (LDL-C)",
        "Very Low Density Lipoprotein Cholesterol (VLDL-C)",
        "Apolipoprotein CIII (ApoCIII)",
        "Apolipoprotein A1 (ApoA1)",
        "Apolipoprotein B (ApoB)",
        "Apolipoprotein B48 (ApoB-48)",
        "Apolipoprotein B100 (ApoB-100)",
        "Lipoprotein-a (Lp[a])",
        "Free Fatty Acid (FFA)",
        "Insulin",
        "Plasma Glucose",
        "Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)",
        "Fructosamine",
        "Glycated Albumin",
        "Subcutaneous Adipose Tissue (SAT)",
        "Visceral Adipose Tissue (VAT)",
        "Fatty Liver Index (FLI)",
        "Body Weight",
        "Waist to Hip Ratio"
      ],
      "remaining_candidate_features": [
        "weight",
        "height",
        "history of oral antidiabetic therapy",
        "duration of Type 2 diabetes mellitus",
        "history of hypertriglyceridemia",
        "history of nonalcoholic fatty liver disease (NAFLD)."
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), weight, height, plasma triglycerides (TG) level, hemoglobin A1c (HbA1c) level, hepatic fat fraction (HFF), history of oral antidiabetic therapy, duration of Type 2 diabetes mellitus, history of hypertriglyceridemia, history of nonalcoholic fatty liver disease (NAFLD)."
  }
}